Johnson & Johnson’s Q1 Earnings Beat Estimates, 2025 Guidance Revised To Account For Intra-Cellular Therapies Acquisition: Retail’s Positive

Barchart · 5d ago
The company said the updated guidance includes costs estimated to be incurred as part of Trump’s tariffs on certain imports into the U.S.
This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.